For qualitative detection of:

Bilharzia (*Schistosomiasis*)

(25 Diagnostic tests)
URINE CCA TEST FOR SCHISTOSOMIASIS (BILHARZIA)

INDICATIONS FOR USE:
The urine-CCA (Circulating Cathodic Antigen) cassette test is for the qualitative presumptive detection of an active *Schistosoma* infection, more specific *S. mansoni*, but also other species e.g. *S. haematobium* and *S. japonicum*. Levels in urogenital schistosomiasis are variable, and also seem to differ between regions. In general, medium to high level infections with *S. haematobium* can be diagnosed using the urine CCA strip. This test should be used for patients with clinical signs and symptoms that are consistent with a Bilharzia infection.

For endemic studies involving *S.mansoni* infections, a single CCA urine test demonstrates closely the true prevalence predicted by models based on multiple egg count determinations.

CLINICAL SIGNIFICANCE:
The urine-CCA cassette test is a fast and easy to perform methodology in the presumptive detection of Bilharzia in persons with clinical signs and symptoms consistent with an active bilharzia infection. A positive test result indicates an active infection. The test should only be used as one of the aids for the treating physician in assisting the diagnosis and treatment of an active infection. Positive results are presumptive and should take in account diagnostic regimes such as clinical history, clinical findings, microscopy based diagnosis on urine or stool, serological testing, biopsy and or histological examination of tissue.

The test may be false negative in a low parasitic level of infection. The test result should be interpreted with caution during the premature developmental phases of a bilharzia infection, usually in the first 4-8 weeks after infection which may render a false negative result.

Detection of antibodies against Bilharzia may further confirm the clinical suspicion. These antibodies however may persist for many years, even after successful treatment, making the diagnosis of a re-infection or the diagnosis of an unsuccessful treatment very cumbersome. Antibodies may also be absent in certain cases of chronic active infection. According to certain literature successful treatment after one standard recommended dose of chemotherapy is 65-85%. CCA rapidly declines after successful treatment and a positive test result usually becomes negative within 2-3 weeks after treatment. Re-infection may occur rapidly resulting in a positive test result within 6-10 weeks after initial successful chemotherapy.

INTRODUCTION:
Schistosomes are blood-dwelling flukes belonging to the class Trematoda, but differ from other trematodes having separate adult male and female parasites. Sexual reproduction happens in the definitive host (humans, cattle, etc), depending on the Bilharzia species and the asexual reproduction phase happens in the snail (intermediate host). Cercaria (released by specific snail species in the water) enters the human body through the skin. The young schistosomulum is most susceptible to immune
damage. Employing certain evasion mechanisms, the worm becomes refractory, or even immunologically unrecognisable to certain aspects of the host defence mechanism. Adult parasites may survive for many years in the host, even up to 40 years.

Approximately after 6 weeks post infection the adult worm-pairs start to lay eggs which penetrate the intestinal wall (S. mansoni, S. japonicum) or the bladder wall (S. haematobium) and will be passed out via the faeces or urine. A considerable proportion of eggs are not excreted but remain stuck in the tissue inducing granuloma formation with subsequent complications to the different organs affected.

The gastrointestinal duct of a schistosome is a cul-de-sac. The parasite has to regurgitate at regular intervals the undigested particulate as well as “parasitic gut associated glycoproteins”. One of the major antigens regurgitated by the parasites is CCA (Circulating Cathodic Antigen). Although Bilharzia eggs also release CCA antigen it is in minute quantities. The major source of CCA originates from live adult worms.

**DIAGNOSIS OF BILHARZIA:**

Laboratory diagnosis of Bilharzia is usually performed by microscopical detection of eggs in urine or stool or by immunological methods (antibody or antigen detection).

Microscopic diagnosis is currently the most generally used method for detecting and confirmation of active Bilharzia. However, expert microscopic diagnosis is often not immediately available, and thus may delay the treatment in clinical suspected patients, or it may be unreliable or absent in remote areas. The sensitivity of microscopic examinations also depends on the severity of the infection. In low grade infections, the sensitivity of one microscopic examination may be as low as 20%. In clinically suspected cases up to 5 urine specimens (collected over midday), and or 5 stool specimens for microscopic examinations are recommended to increase the sensitivity of the tests.

Due to immune modulation the infected host may show a separate IgG, IgM, IgA and IgE antibody response, or a combination of these isotypes. As much as 14% of patients may not respond with any antibody formation. Depending on the methodology used and the timing in the post infected host, the sensitivity of current antibody assays is not optimal (ranging from 65 to 86%). Some of the commonly used methodologies are based on detection of antibodies directed against the soluble egg antigen (SEA).

Due to the retention of eggs and the constant secretion of SEA by the deposited eggs, antibodies may be elicited for an indefinite period after the primary infection, irrespective of successful treatment.

The urine-CCA cassette test detects the parasite antigen CCA which is present in all Schistosoma species, including animal species. The major portion of CCA released by the adult live parasite is secreted in the urine. A positive CCA test result on randomly collected midstream urine indicates an active Bilharzia infection.
TEST PRINCIPLE:
After applying the urine, the CCA antigen that may be present in the sample binds to the labelled monoclonal antibody immobilized on the sample membrane. The solution then runs over the strip where the antigen-antibody complex attaches to another monoclonal antibody immobilized at the test line. A pink-coloured line develops. The second line is a procedural control, which should always show up to make sure the test works correctly. The intensity of the line is qualitatively related to the intensity of the infection.

SPECIMEN COLLECTION AND PREPARATION:
A randomly collected midstream urine specimen.

KIT COMPONENTS:
Each kit contains the following components in sufficient quantities to perform the number of tests indicated on the package label:
- 25 x Test Cassettes each individually packaged
- 1 x Instructions for Use
- 1 x 3 mL Bottle of Buffer
- 25 x urine collection devices (plastic pipettes)

PRECAUTIONS:
1. Keep storage boxes dry.
2. Do not reuse test cassettes.
3. Do not use test cassettes if foil pouch is punctured or damaged.
4. Never pipette by mouth or allow reagents or patient sample to come into contact with skin.
5. Optimal results will be obtained by strict adherence to this protocol. Reagents must be added carefully to maintain precision and accuracy.
6. Performing the assay outside the prescribed time and temperature ranges may produce invalid results. Assays not falling within the established time and temperature ranges must be repeated.
7. The components in this kit have been quality control tested as a master lot unit. Do not mix components from different lot numbers. Do not mix with components from other manufacturers.
8. Care should be exercised to protect the reagents in this kit from contamination. Do not use if there is evidence of microbial contamination or precipitation. Biological contamination of dispensing equipment, containers or reagents can lead to false results.
9. Do not heat-inactivate samples.
10. All human urine products should be handled as potentially infectious material.
11. Waste disposal. Testing materials should be disposed of in accordance with local, state and/or federal regulations.
**ASSAY PROCEDURE:**

**Note:** Ensure all reagents are equilibrated to room temperature (20-25ºC) before commencing the assay.

Remove the Test Cassette and Collection Device from their pouches just prior to use.

- Squeeze the pipette bulb and insert the tip into the urine sample.
- Allow the sample to fill up by gently releasing the bulb.

- Transfer 1 drop of urine to the circular well of the test cassette by gently squeezing the bulb.
- Allow the sample to absorb entirely into the specimen pad within the circular well.

- Hold the Buffer bottle vertically and 1cm above the circular well.
- Add 1 drop of Buffer.

- Read the result exactly **20 minutes** after adding Buffer to the Test Cassette.
- Any results read outside **25 minutes** should be considered **invalid** and must be repeated.
- The **blue** control line must turn **pink**. If the control line stays blue the test should be considered **invalid**.
- Any line in the test area should be considered positive.
**INTERPRETATION OF RESULTS:**

**POSITIVE**

| Image | Control band turns pink.  
|-------|---------------------------------------------------------------|
|       | A band is present in the test T area.  
|       | The test is positive for Bilharzia.                          |

**NEGATIVE**

| Image | Control band turns pink.  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No test T band present.</td>
</tr>
<tr>
<td></td>
<td>Demonstrates the test was performed correctly but no Bilharzia antigens were detected.</td>
</tr>
</tbody>
</table>

**INVALID**

| Image | Control line stays blue.  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only a pink control line should be considered positive.</td>
</tr>
<tr>
<td></td>
<td>The test is invalid and should be repeated.</td>
</tr>
</tbody>
</table>

| Image | A test line with no control line.  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A pink control line must be present.</td>
</tr>
</tbody>
</table>

**CROSS-REACTIVITY:**

Urinary tract infections or haematuria may sometimes cause false positive results.

**QUALITY CONTROL:**

Quality Control (QC) requirements must be performed in conformance with local, state, and/or federal regulations or accreditation requirements and your laboratory’s standard QC procedures.

**TEST LIMITATIONS:**

1. The analysis of a single test sample should not be used as the sole criteria for diagnosis.

2. In early infections detectable levels of antigen may be absent. The worm load will also determine the sensitivity of the test.

3. In suspected clinical cases of Bilharzia, it should be kept in mind that the test may be false negative during the parasitic developing phase (first 6-7 weeks).

4. Re-testing or alternative testing methodologies should be considered in such cases. Further investigation of negative results is therefore important.

5. Haematuria or pio-uria may cause a false positive test. It is of importance that a midstream urine specimen randomly collected should be obtained.
6. The final diagnosis should be based on the test result in conjunction with other clinical and or laboratory findings.

7. The continued presence or absence of CCA may be used to determine the failure or success of therapy.

8. CCA in urine decreases usually already the next day, and should become undetectable 2-3 weeks after successful treatment.

**STORAGE AND SHELF LIFE OF REAGENTS**
1. Store kit between 4 and 28°C. Constant storage temperature must be maintained for the reagents to be stable until the expiry date of the kit. Refer to package label for expiry date.
2. Do not freeze kit components.
3. The test kit may be used until the expiry date marked on the package label.
4. Do not use reagents beyond the expiry date.

**STORAGE AND STABILITY OF URINE SAMPLES**
1. Patient urine samples can be stored at 4ºC for at least 7 days.
2. Patient urine samples can be stored at -20ºC for at least 1 calendar year.

**PERFORMANCE EVALUATION DATA**

**Sensitivity and specificity**
The sensitivity of the test varies with the intensity of the infection. Compared to the field gold standard for *S. mansoni*, microscopic egg determination, for intensities higher than 400 egg per gram of faeces, sensitivity is 100%. In low positive cases, the sensitivity can decrease to about 70%. However, also egg determination is highly variable and therefore show decreased sensitivity, resulting in a comparable performance of both tests in field situation. For endemic studies, a single CCA urine test demonstrates closely the true prevalence predicted by models based on multiple egg count determinations. The specificity in negative endemic populations is usually around 95%.

**Lowest detectable limits**
In experimental animal models (baboons) it was determined that CCA can be detected in infections with about 50 worms and higher. The limit of detection by the CCA urine strip is comparable to the limit of detection by egg counts.

**Schistosoma species differentiation**
The highest concentrations of CCA are detected in *S. mansoni* infections, and therefore the test is particularly useful to diagnose intestinal schistosomiasis. Levels in urogenital schistosomiasis (*S. haematobium*) are variable, and also seem to differ between regions. In general there is a link between the sensitivity of the test and the intensity of the *S. haematobium* infection. Medium to high level infection with *S. haematobium* can be diagnosed using the urine CCA strip.

**DISCLAIMER**
The entire risk as to the performance of these tests and the use of the products is assumed by the purchaser. Rapid Medical Diagnostics shall not be liable for indirect, special or consequential damages of any kind resulting from the use of these products.
BIBLIOGRAPHY
References to published papers on the use of CCA urine strips.


Basic studies of CCA in urine


Assessment of cure


Diagnosis of Bilharzias
